New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Creative Commons License

Kozanoglu I., Yandim M. K., Cincin Z. B., Ozdogu H., Cakmakoglu B., Baran Y.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.139, sa.2, ss.327-335, 2013 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 139 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00432-012-1331-y
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.327-335
  • Abdullah Gül Üniversitesi Adresli: Hayır

Özet

Propranolol, a non-selective beta-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that beta-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranolol-induced apoptosis in multiple myeloma cells.